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Schaller et al 337Methods: This 12-week, multicenter, randomized, investigator-blinded, parallel-group comparative study
randomized adult subjects with severe rosacea (Investigator’s Global Assessment [IGA] score, 4) to receive
either IVM and DMR (combination arm) or IVM and placebo (monotherapy).Results: A total of 273 subjects participated. IVM and DMR displayed superior efficacy in reduction of
inflammatory lesions (e80.3% vs e73.6% for monotherapy [P = .032]) and IGA score (P = .032).
Combination therapy had a faster onset of action as of week 4; it significantly increased the number of
subjects achieving an IGA score of 0 (11.9% vs 5.1% [P = .043]) and 100% lesion reduction (17.8% vs 7.2%
[P = .006]) at week 12. Both treatments reduced the Clinician’s Erythema Assessment score, stinging/
burning, flushing episodes, Dermatology Life Quality Index score, and ocular signs/symptoms and were
well tolerated.Limitations: The duration of the study prevented evaluation of potential recurrences or further
improvements.Conclusion: Combining IVM and DMR can produce faster responses, improve response rates, and increase
patient satisfaction in cases of severe rosacea. ( J Am Acad Dermatol 2020;82:336-43.)
Key words: clear; combination therapy; concomitant use; doxycycline; individualized treatment;
ivermectin; rosacea; rosacea treatment; severe rosacea.CAPSULE SUMMARY
d Combination therapy may be
complementary in the treatment of
moderate to severe rosacea and better
than monotherapy in many subjects.
d Adding doxycycline 40-mg modified-
release capsules, to daily ivermectin 1%
cream can produce faster responses,
improve response rates, and increase
patient satisfaction in cases of severe
rosacea compared with 1% ivermectin
alone.Rosacea is a chronic in-
flammatory disease of the
skin that displays a broad
diversity of clinical manifes-
tations1 from erythema to
inflammatory lesions and
phymata, as well as ocular
symptoms.2 Combination
therapy with topical and
oral agents has become a
common treatment option
for patients with moderate
or severe rosacea present-




tion therapy might be preferable to
monotherapies.3
Studies of combination therapy in rosacea are
limited, with a lack of high-level evidence regarding
the superiority of a combination therapy approach.5
The topical agents evaluated in previous combination
therapy studies are metronidazole and azelaic acid,
primarily with oral doxycycline.6 Concomitant use of
ivermectin 1% cream (IVM) (Soolantra cream,
Galderma Production Inc, Montreal, Canada) and
brimonidine 0.33% gel (Mirvaso gel, Galderma
Production Inc, Alby-sur-Cheran, France, and
D€usseldorf, Germany) demonstrated superior efficacy
regarding erythema and inflammatory lesions.7Another study found that a
combinationofmetronidazole





demonstrated a greater mean
reduction in inflammatory
lesion counts from baseline
to week 12 than did metroni-
dazole 1% gel (MetroGel
gel, Galderma Production
Inc, Quebec, Canada) alone.8
Additionally, IVM once daily
showed superiority to metro-
nidazole 0.75% cream twicedaily in terms of percentage reduction of inflam-
matory lesion counts and improvement in quality of
life.9-11 Because IVM and DMR may have both
different and shared molecular targets in the in-
flammatory cascade of rosacea and because it is
known that 2 agents may increase efficacy regard-
less of whether they act on different or common
targets, their combined use may result in comple-
mentary action, superior efficacy, and an optimized
clinical outcome.12
The main objective of the present study was to
evaluate the efficacy of concomitant use of IVM and
DMR versus that of IVM and placebo (PBO) in the
treatment of severe rosacea.
Fig 1. Rosacea. Subject disposition. AE, Adverse event:
DMR, doxycycline 40-mg modified-release capsules; IVM,
ivermectin 1% cream; PBO, placebo.
Abbreviations used:
AE: adverse event
CEA: Clinician’s Erythema Assessment
DLQI: Dermatology Life Quality Index
DMR: doxycycline 40-mg modified-release
capsules
IGA: Investigator’s Global Assessment
ITT: intent-to-treat
IVM: ivermectin 1% cream
LOCF: last observation carried forward
PBO: placebo
SD: standard deviation
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Study design and randomization
This was a multicenter, randomized, investigator-
blinded, parallel-group comparison, 12-week, phase
3b/4 study. Subjects underwent 4 visits: a baseline/
screening visit and visits at weeks 4, 8, and 12.
Before study initiation, a randomization list was
generated by Galderma R&D. The RANUNI routine
of the SAS software (SAS Institute Inc, Cary, NC)
system was used to generate kit numbers, each of
which was assigned to a subject by the investigator.
The randomization list was accessible only to desig-
nated personnel responsible for labeling and
handling the study treatments.
Subjects were randomized (1:1) to receive
12 weeks of combination therapy (IVM and DMR)
or monotherapy (IVM and PBO). Treatment was
allocated following the randomization list in chro-
nologic order of inclusion. Investigators were kept
blinded by restricting their contact with the study
treatments.
Study participants
Subjects were recruited from 39 sites in the United
States, Canada, Germany, Czech Republic, Hungary,
and Poland. Eligible subjects had severe rosacea
(Investigator’s Global Assessment [IGA] score of 4),
were at least 18 years old, and had 20 to 70 inflam-
matory lesions (papules and pustules) and no more
than 2 nodules on the face. The ethical principles of
the Declaration of Helsinki (1964) and subsequent
amendments and applicable regulatory require-
ments were followed. All subjects provided written
consent.
Treatment
Subjects were instructed to apply IVM once daily
in the evening, avoiding the eyes, eyelids, inner
nose, mouth, and lips, and to take DMR or PBO once
daily (preferably while fasting in the morning).
Subjects were provided with and instructed to use
controlled, rosacea-specific, noninvestigational skincare products: gentle skin cleanser (Cetaphil
Redness Relieving Foaming Face Wash [Galderma]
before application of the study treatment) and facial
moisturizer (Cetaphil Redness Relieving Facial
Moisturizer [Galderma], sun protection factor 30 [20
in the United States], within 1 hour after application
of the study treatment).Study end points
The primary end point was the percentage change
from baseline in inflammatory lesion count at week
12.
Secondary end points included percentage
change from baseline in inflammatory lesion count
at each intermediate visit; Clinician’s Erythema
Assessment (CEA), IGA, and stinging and burning
at each postbaseline visit; global improvement in
rosacea at the last visit; and percentage change from
baseline in terms of flushing count per week over
12 weeks (medical history based on diaries kept
beginning a week before starting treatment).
Other end points included global assessment of
ocular signs and symptoms, if present at baseline, at
each postbaseline visit (0-4 scale: 0, no ocular
sign/symptom; 1, mild blepharitis with lid margin
telangiectasia; 2, blepharoconjunctivitis; 3, blephar-
okeratoconjunctivitis; and 4, sclerokeratitis, anterior
uveitis); Dermatology Life Quality Index (DLQI)
questionnaire results at baseline and last visit; and
subject satisfaction questionnaire at last visit.
Fig 2. Rosacea. Mean percentage reduction of inflammatory lesions from baseline to week 12
(intent-to-treat/last observation carried forward population). Ivermectin 1% cream (IVM) and
placebo (PBO) (n = 138); IVM and doxycycline 40-mg modified-release capsules (DMR)
(n = 135). *P = .007; yP\ .012; zP = .032.
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between-treatment differences in the proportion of
subjects with IGA and CEA scores of 0 at week 12; the
difference from baseline to week 12 in the propor-
tion of subjects with stinging and burning, flushing,
and ocular signs and symptoms; and the difference
from baseline to last visit in the total mean DLQI
score.
Adverse events (AEs) were recorded at each visit.
Statistical methods
Sample size was calculated on the basis of
historical data from studies conducted with IVM
and DMR as monotherapies.13-15 Considering a 15%
rate of subjects excluded from the analysis at week
12, 135 subjects per group were to be enrolled to
demonstrate at least a 15% difference at week 12with
90% power.
All variables were analyzed in the intent-to-treat
(ITT) population, except for safety variables that
were analyzed in all subjects treated. Last observa-
tion carried forward was the primary method for
imputation of missing data. The primary efficacy end
point was analyzed by using the Cochran-Mantel-
Haenszel method (the FREQ procedure from SAS
software), stratified by center (or analysis center)
after ridit transformation with row mean difference
statistics, testing the hypothesis of equality on the
ITT/last observation carried forward population. The
same method was used for secondary end points,
patient-reported outcomes, and post hoc analyses.
RESULTS
Subjects
A total of 273 subjects were enrolled and random-
ized in the study, of whom 251 (91.9%) completedthe study (Fig 1 [first subject screened on July 5, 2017;
last subject completed the study on February 8,
2018]). At baseline, the groups were similar. All
subjects had severe rosacea (IGA score, 4) and
suffered from erythema classified as severe (CEA
score, 4) in 60.4% of subjects and moderate in 30.0%
of subjects. In addition, more than 85% of subjects
reported skin stinging and burning, and more than
40% had ocular signs and symptoms. On average,
subjects experienced approximately 5 episodes of
flushing per week. Despite having severe rosacea,
56% of all subjects had not received any therapy for it
in the past 6 months. Common previous therapies
included metronidazole (26.3%), tetracyclines
(10.3%), and ivermectin (6.2%). Among the subjects
who received prior therapies, 64.8% had used only
topical treatments, 25.3% had used both oral and
topical treatments, and 9.9% had taken only oral
treatments.
Efficacy
Both treatments resulted in a reduction of inflam-
matory lesions from baseline. This reduction was
significantly greater in subjects receiving combina-
tion therapy than in those receiving monotherapy
starting from week 4 (P = .007) across subsequent
time points (Fig 2), suggesting a potentially faster
onset of efficacy with the combination therapy over
monotherapy. The mean percentage reduction in
inflammatory lesions at week 12 was e80.3 6 21.7
versus e73.6 6 30.5 (P = .032) (Fig 2), with median
values of e85.9 and e84.2 for combination therapy
and monotherapy, respectively. Combination
therapy also led to a higher proportion of subjects
achieving 100% lesion clearance at week 12 (17.8%
vs 7.2% for monotherapy [P = .006]). In addition,
Fig 3. Rosacea. Investigator’s Global Assessment (IGA)
score assessed at week 12 (intent-to-treat/last observation
carried forward population). Ivermectin 1% cream (IVM)
and placebo (PBO) (n = 138); IVM and doxycycline 40-mg
modified-release capsules (DMR) (n = 135).
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ment in IGA scores at all time points (P \ .05),
including at week 12 (P = .032), with a higher
proportion of subjects with an IGA score of 0 (clear)
at week 12 than in the group treated with mono-
therapy (11.9% vs 5.1% [P = .43] [post hoc analysis])
(Fig 3).
Other rosacea symptoms similarly improved with
either treatment. Both treatments reduced CEA
scores from baseline to week 12. The proportion of
subjects with a CEA score of 0 (clear) increased more
rapidly with combination therapy, and at week 12
the proportion was 14.1% versus 7.2% with mono-
therapy (P = .087 [post hoc analysis]). Most subjects
experienced a reduction in skin stinging and burning
from baseline, with approximately 74% of subjects in
both groups being symptom-free at week 12
(P\ .001 for both treatments [post hoc analysis]).
On average, the number of flushing episodes per
week decreased from baseline to week 12 (by
e55.76 96.4% ande62.66 61.0%with combination
therapy and monotherapy, respectively). In addi-
tion, the proportion of subjects without flushing (no
episodes) increased from baseline to week 12 by
47.2% with combination therapy and by 41.9% with
monotherapy (P\.001 for both treatments; post hoc
analysis).
Both treatments also reduced the proportion of
subjects with ocular signs and symptoms from
baseline to week 12: e60.0% with combination
therapy and e60.7% with monotherapy (P \ .001
for both treatments [post hoc analysis]).
Overall, for both treatments, approximately 95%
of subjects evaluated their rosacea as improved in
comparison with their condition before the study.
Photographs of subjects at baseline and week 12 are
presented in Figs 4 and 5.Patient-reported outcomes
The DLQI score was substantially improved from
baseline, with the percentage of subjects experi-
encing no effect on their quality of life ranging from
less than 20% at baseline to higher than 65% at last
visit (in both treatment arms). Mean changes in DLQI
score improved by last visit and reached the minimal
clinically important difference (mean change,
e4.4 6 5.1 with combination therapy and
e4.3 6 5.8 with monotherapy [P \ .001 for both
treatments, post hoc analysis]).16 In particular, the
proportion of subjects without itchiness, soreness,
painfulness, or stinging increased from baseline to
last visit: from 23.7% and 21.7% to 72.8% and 63.6%
with combination therapy andmonotherapy, respec-
tively. Similarly, the proportion of subjects who did
not experience embarrassment and self-
consciousness increased from baseline to last visit:
from 20.0% and 15.9% to 72.0% and 66.7% with
combination therapy and monotherapy, respec-
tively. Although more subjects were satisfied overall
or very satisfied with combination therapy than with
monotherapy (93.6% vs 79.8%), the difference was
not significant.
Safety
The safety population comprised all 273 subjects
in the ITT population. The incidence of treatment-
related AEs was generally low, although slightly
lower in subjects receiving combination therapy
(4.4% vs 7.2% for monotherapy). Most treatment-
related AEs were dermatologic and reported with
similar frequency in subjects receiving combination
therapy or monotherapy (2.2% vs 2.8%, respec-
tively). Gastrointestinal treatment-related AEs were
reported in a small proportion of subjects: in 1.5%
versus 2.9% for combination therapy and monother-
apy, respectively. Treatment-related AEs leading to
discontinuation were reported only in subjects
receiving monotherapy (2.2%).
DISCUSSION
This study demonstrated that the combination of
IVM and DMR was significantly superior to IVM and
PBO (monotherapy) in terms of percentage reduc-
tion in inflammatory lesions from baseline and the
proportion of subjects achieving 100% lesion clear-
ance at week 12. The significantly greater proportion
of clear subjects (IGA score, 0 [ie, with no inflamma-
tory lesions or erythema]) at the end of the study was
more than 2-fold higher with combination therapy
than with monotherapy. This is an important finding
in light of a recent pooled analysis demonstrating
that patients who had an IGA score of 0 (clear)
exhibited a better quality of life and longer time to
Fig 4. Rosacea. Photographs of a male subject in the ivermectin 1% cream (IVM) and placebo
(PBO) treatment arm at baseline with 69 inflammatory lesions, an Investigator’s Global
Assessment (IGA) score of 4, and a Clinician’s Erythema Assessment (CEA) score of 3 (A) and at
week 12 with 25 inflammatory lesions, an IGA score of 2, and a CEA score of 2 (B).
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(‘‘almost clear’’).17 As the burden of rosacea trans-
lates to impaired quality of life, treating until clear
represents an optimal approach to relieving the
burden of rosacea and is a rational goal to strive for
when evaluating rosacea improvement.18
In terms of erythema, both treatments similarly
reduced the CEA score. Although the proportion of
subjects with clear skin (CEA score, 0) at week 12
nearly doubled with combination therapy compared
with monotherapy, the groups were not significantly
different. This observation is not surprising, espe-
cially with the high mean number of papulopustular
lesions at baseline, as IVM and DMR can both
independently reduce inflammatory lesions, which
could lead to a concurrent reduction in lesional and
perilesional erythema. Furthermore, a meta-analysis
in patients with rosacea revealed an increased
density of Demodex mite infestation not only when
papules and pustules were present, but also in
association with erythema.19 As both treatment
arms included IVM, it can be speculated that
improvement of erythema, especially when associ-
ated with papulopustular lesions, may be related to
both the anti-inflammatory and acaricidal effects of
IVM.20Importantly, this study also supports the high
efficacy of IVM in subjects with severe rosacea and its
role in this combination therapy. Observed reduc-
tions in erythema, stinging and burning, flushing
episodes, and ocular signs and symptoms, and the
improvement in quality of life were similar between
treatments. Amelioration of the patient’s general
outlook regarding their physical appearance and
improvement in their quality of life may in turn
reduce their overall stress level, with increased stress
being reported to be a potential inducer of flushing
in rosacea.21
Although the 2 study treatment regimens ex-
hibited similar efficacy for several of the assessed
variables, the beneficial effects in terms of reduction
in percentage of inflammatory lesions and increase
in proportion of subjects with a CEA score of 0 (clear
skin) were noticeable earlier with combination
therapy. The quicker onset of these visible effects
is likely to result in enhanced patient adherence to
treatment and better outcomes.
A surprising outcome from this study was the
improvement in ocular signs and symptoms. Despite
instructions to avoid application of IVM to the eyelid
area, both treatments resulted in a significant reduc-
tion in ocular signs and symptoms. The overall
Fig 5. Rosacea. Photographs of a female subject in the ivermectin 1% cream (IVM) and
doxycycline 40-mg modified-release capsules (DMR) treatment arm at baseline with 66
inflammatory lesions, an Investigator’s Global Assessment (IGA) score of 4, and a Clinician’s
Erythema Assessment (CEA) score of 4 (A) and at week 12 with 13 inflammatory lesions, an IGA
score of 3, and a CEA score of 3 (B).
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a concurrent reduction in eyelid inflammation as
well, thereby reducing ocular signs and symptoms. A
particularly notable result is the reduction in stinging
and burning shown here and in previous clinical
trials,9,10,13 as these symptoms can substantially add
to patient discomfort whereas their impact is often
underestimated by physicians.18
Limitations to this study include the fact that
diagnosis of the severity of ocular rosacea was not
undertaken by ophthalmologists and other
ocular diagnoses could have confounded these
results. Nevertheless, as described in treatment
recommendations that involved ophthalmologists,
dermatologists are expected to recognize most
features of ocular rosacea, but not to manage
anything beyond mild cases.3 Moreover, further
studies of ocular rosacea are necessary, as high-
lighted by a recent Cochrane review that identified
only 2 studies with usable data yet with a low
quality level of evidence.5 Other limitations
include lack of a control group and the short study
duration, which did not allow for evaluation of
possible recurrences.
Although both treatments were well tolerated, the
incidence of treatment-related AEs was lower withcombination therapy than with monotherapy. In
addition, there were no treatment-related AEs lead-
ing to discontinuation in subjects taking combination
therapy and the presence of DMR did not increase
the incidence of gastrointestinal treatment-related
AEs. These data show that the better efficacy profile
observed with combination therapy is not likely to
compromise the safety profile, resulting in a
favorable risk-benefit balance. Proper skin care
may reduce the incidence of dermatologic AEs,
possibly owing to improvements in the skin barrier.7
Therefore, the use of rosacea skin care products
might have contributed to the overall positive
tolerability and safety profile.
In conclusion, these study results suggest that
using a combination of IVM and DMR, each once
daily, along with a properly selected skin care
regimen, can improve treatment results. Faster onset
of visible improvement, greater efficacy, a reduction
in flushing episodes, and a decrease in facial stinging
and burning were all observed, offering the
opportunity to reach skin clearance (IGA score, 0)
in more patients while not compromising safety.
Ultimately, overall patient satisfaction was achieved
more frequently in those subjects who utilized the
combination therapy.
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